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Abstract: The Genome Aggregation Database presently contains >120,000 human genomes.
We searched in this database for the presence of mutations at the sites of tetanus (TeNT) and
botulinum neurotoxins (BoNTs) cleavages of the three SNARE proteins: VAMP, SNAP-25 and
Syntaxin. These mutations could account for some of the BoNT/A resistant patients. At the same time,
this approach was aimed at testing the possibility that TeNT and BoNT may have acted as selective
agents in the development of resistance to tetanus or botulism. We found that mutations of the
SNARE proteins are very rare and concentrated outside the SNARE motif required for the formation
of the SNARE complex involved in neuroexocytosis. No changes were found at the BoNT cleavage
sites of VAMP and syntaxins and only one very rare mutation was found in the essential C-terminus
region of SNAP-25, where Arg198 was replaced with a Cys residue. This is the P1’ cleavage site
for BoNT/A and the P1 cleavage site for BoNT/C. We found that the Arg198Cys mutation renders
SNAP-25 resistant to BoNT/A. Nonetheless, its low frequency (1.8 × 10−5) indicates that mutations
of SNAP-25 at the BoNT/A cleavage site are unlikely to account for the existence of BoNT/A resistant
patients. More in general, the present findings indicate that tetanus and botulinum neurotoxins have
not acted as selective agents during human evolution as it appears to have been the case for tetanus
in rats and chicken.
Keywords: ExAC; gnomAD; botulinum neurotoxin; tetanus neurotoxin; SNAP-25; VAMP-1/2;
syntaxin-1A/1B
1. Introduction
A large effort is underway to catalogue variation in human genome and exomes (protein-coding regions
of genes) in order to identify human mutations and their relation to a given pathological phenotype [1–3].
The largest database presently available is provided by the Exome Aggregation Consortium (ExAC)
that stores in a publicly accessible library a data set spanning >60,000 exomes of European, African,
South Asian, East Asian, and admixed American (Latino) ancestry [3] (http://exac.broadinstitute.org/about).
More recently, this database has merged into the Genome Aggregation Database (gnomAD) raising the
number of exomes to more than 120,000 and including about 16,000 genomes collected from various
disease-specific individuals and population genetic studies (http://gnomad.broadinstitute.org/about).
This has greatly increased the significance of finding mutations.
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Whole exome/genome sequencing data have already provided very useful information and
have led to the remarkable evidence that humans can carry known pathogenic mutations without
being affected by the previously reported and associated disease [3–6]. Here, we have considered
how human mutations can impact on the possibility of being affected by tetanus and botulism.
These two neuroparalytic diseases are caused by the most potent bacterial exotoxins known to
humans, i.e., tetanus and botulinum neurotoxins (TeNT and BoNTs), that enter nerve terminals
and display a very specific metalloprotease activity directed to the three SNARE (Soluble NSF
Attachment Protein Receptor) proteins VAMP (vesicle associated membrane protein, also known as
synaptobrevin), SNAP-25 (synaptosomal-associated protein 25) and syntaxin (STX) [7,8]. These three
proteins contain α-helical SNARE motifs that are capable of coil-coiling with each other forming the
SNARE complex which is the core of the nanomachine mediating synaptic vesicle fusion with the
plasma membrane [9]. Each neurotoxin cleaves a specific SNARE protein at a distinct peptide bond
and prevents the release of neurotransmitters causing a reversible peripheral neuroparalysis [10–12]:
TeNT and BoNT/B cleave the Q76(P1 site)-F77(P1’ site) (human numbering from here following)
peptide bond of VAMP-2 [13], BoNT/D and /DC cleave the K59-L60 bond [14,15], BoNT/F1 cleaves
the Q58-K59 bond [16], BoNT/G cleaves the A81-A82 bond [17]. More recently it was found that
BoNT/F5 and BoNT/FA (also known as BoNT/H) hydrolyses the L54-E55 bond of VAMP-2 [18,19],
and BoNT/X cleaves R66-A67 [20]. The BoNT-like protease of Weissella oryzae cleaves the W89-W90
peptide bond of VAMP [21]. BoNT/A cleaves the Q197-R198 bond at the C-terminus of the second
SNARE motif of SNAP-25, whereas BoNT/E hydrolyses the R180-I181 peptide bond of the same
protein [14,22–24]. BoNT/C is unique because it hydrolyses both SNAP-25 (at R198-A199) and STX-1A
(at K253-A254) as well as STX-1B (at K252-A253) [25]. Such molecular lesions cause a persistent
inhibition of neurotransmitter release with the consequent spastic neuroparalysis of tetanus and the
flaccid neuroparalysis of botulism [26]. The long duration (3/4 months) of the BoNT/A induced
paralysis in humans and its complete reversibility is at the basis of its large use in human therapy and
cosmesis [10].
Previously, rats and chickens were found to be resistant to tetanus because VAMP-1, which is the
predominant form of VAMP in the spinal cord, is mutated at the TeNT cleavage site [27]. In addition,
evidence was provided recently that BoNT/D may have acted as a selective agent in animal botulism,
and it was suggested that the presence of Ile at position 48 of VAMP-1 in place of Met is responsible
for the resistance of humans to BoNT/D [28,29]. Using the ExAC and gnomAD databases, we tested
whether human SNARE proteins display increased variability at the cleavage sites of TeNT and
BoNTs which would indicate that these neurotoxins may have acted as selective agents driving the
evolution of human SNARE proteins. At the same time, we tested the possibility that mutation at the
SNAP-25 Q197-R198 peptide bond contributes to the resistance to BoNT/A therapy of some patients.
Interestingly, we only found a mutation in Arg198 of SNAP-25, which is the P1’ site of cleavage by
BoNT/A and, at the same time, the P1 site of cleavage by BoNT/C. Here, we show that the mutant
SNAP-25 is resistant to the metalloproteolytic activity of BoNT/A. Remarkably, no mutations were
found in VAMP-1 and -2 at the proteolytic sites of TeNT and BoNT/B, /D, /F, /G and /X or at those
of BoNT/C on syntaxins 1A and 1B. We also found a rare replacement of Arg68 of VAMP-1 which
is at the cleavage site of BoNT/X. As BoNT/X has never been found to cause botulism in humans,
this finding has not been considered further in the present work. The biological and toxicological
implications of these findings are discussed.
2. Results
2.1. Mutants of the Neuronal SNARE Proteins in Humans
The results of the searches in the ExAC and gnomAD databases for the neuronal isoforms
of syntaxins (STX-1A and STX-1B), of VAMPs (VAMP-1 and VAMP-2) and SNAPs (SNAP-25 and
SNAP-23) are reported in Figures 1–3, respectively. We considered here only the protein-coding
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genetic variants (translated region) leading to mutations with respect to the canonical sequence of the
corresponding protein. The first general comment is that, in comparison to proteins known to carry
high sequence variability without functional consequences, e.g., major histocompatibility complex
proteins (HLA-A/B/C) or olfactory receptors, the number of amino acid substitutions in SNAREs
is dramatically lower, suggesting that they do not tolerate changes which would inevitably lead to
functional alterations [30]. This indicates the very essential nature of their role in the physiology
of the nervous system, so much so that even minor variations probably render the human carrier
non-viable. Further, in agreement with the central role of the SNARE motif [31,32] is the finding
that the few mutations identified are almost invariably outside the essential SNARE motif. However,
some SNARE isoforms seem to tolerate a higher number of mutations, with SNAP-23, VAMP-1 and
STX-1A displaying a higher number of mutants than SNAP-25, VAMP-2 and STX-1B. The reason for this
difference is not apparent as their knock out in animal models lead to non-viability, apart for the STX-1A
knock out mice [33–37]. Accordingly, Figure 1 shows that STX-1A may tolerate many mutations.
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Figure 3. Mutation frequency maps of human SNAP-25 and SNAP-23 proteins. The figure displays
the sequences of SNAP-25 (top) and SNAP-23 (bottom) with respective mutations found in the
gnomAD database (green dots) together with those reported exclusively in the ExAC database
(black squares). Only changes with respect to the canonical sequence of the corresponding protein are
shown. Mutations with frequency higher than 8 × 10−5 are reported i the graph. Below each diagram
a schema ization of the protein prima y sequence, of its domains and of the four palmitoylated cysteines
(in yellow) is given. Arrows indicate the cleavage site of indicated neurotoxins. BoNT/E cleaves at
R180-I181, BoNT/A cleaves at Q197-R198 peptide and BoNT/C cleaves at R198-A199. The red box
indicates the R198C mutation.
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Importantly, it should be noted that mutants of neuronal SNAREs are characterized by an
extremely low frequency in the population of the present data bases, and are never present in
homozygosis indicating that these variations are likely deleterious. Thus, they should be considered as
“mutations” and not “polymorphisms” [38]. This suggests that individuals carrying these mutations
are very likely to be affected by pathological alterations, even though the phenotype is not made
available on the databases. This possibility is consistent with available evidence linking alterations of
SNARE proteins to human neuropsychiatric disorders, like epilepsy, schizophrenia and autism [39–41],
and to significant pathological consequences both in human and in animal models [42–44].
2.2. Mutations of Human SNARE Proteins at the Cleavage Sites of Tetanus and Botulinum Neurotoxins
Figures 1 and 2 show that none of the residues forming the peptide bond cleaved by TeNT or
BoNT proteases within VAMP-1/2 and STX-1A/1B are mutated. This indicates that these very potent
neurotoxins have not acted significantly as selective agents during human evolution. At variance,
the red rectangle in the top panel of Figure 3 highlights a mutation in SNAP-25, where Arg 198 is
replaced by Cys at the cleavage sites of BoNT/A and /C. This mutation is very rare as it has been
detected in 2 out of >120,000 subjects and in both cases in heterozygosis. At variance from VAMPs
and syntaxins, SNAP-25 and SNAP-23 are not integral proteins of the membrane and are also unique
among SNARE proteins as they contain two SNARE motifs (Figure 3). In fact, SNAP-25 and SNAP-23
are attached to the cytosolic face of the plasma membrane or of intracellular organelles, like synaptic
vesicles, via palmitoylated cysteine quartets (residues 85–92 and 79–87, respectively, in yellow) located
in between the two SNARE motifs [45,46].
R198 is the P1’ site of the peptide bond cleaved by BoNT/A. Because of the presence of the sulfur
atom, the volume of the lateral chain of Cysteine is much larger and hydrophobic than that of Arginine,
which is also positively charged at physiological pH values. Thus, it is very likely that Cysteine may
not fit within the active sites of BoNT/A and /C, making SNAP-25 R198C resistant to these BoNTs.
We tested this possibility by generating a recombinant protein consisting of an N-terminal His-tag
followed by a CPV and the second SNARE motif of SNAP-25 (Figure 4A), which is the target substrate
of BoNT/A. The protein was created both with the wild type sequence and the R198C mutation,
and susceptibility to proteolysis by the neurotoxin was tested.
The SDS-PAGE analysis of Figure 4B shows that BoNT/A cleaves with high efficiency wild
type SNAP-25, whilst the mutated recombinant SNAP-25, under these experimental conditions,
is completely resistant. This result is even more evident in Western blot, using an antibody that
specifically stains the C-terminus generated in SNAP-25 after BoNT/A proteolysis. Figure 4C also
shows that the same mutation does not affect BoNT/E activity, as evidenced both by SDS-PAGE and
Western blotting, using antibodies directed against the His-tag or against intact SNAP-25. This latter
result suggests that the mutation does not impact on the folding of SNAP-25, and excludes the
possibility that the lack of cleavage by BoNT/A derives from protein aggregation via disulfide bridging.
Since BoNT/C proteolyzes its substrates very poorly in the test tube [47] and the recombinant
mutated SNAP-25 does not transfect efficiently in neurons in culture, the effect of mutation on BoNT/C
activity could not be investigated. In addition, BoNT/C does not cause botulism in humans [7],
and therefore it cannot have acted, in any case, as a selective agent for human SNARE proteins.
However, considering that R198 is the P1 site of the peptide bond hydrolyzed by BoNT/C [48],
we predict that this mutation will similarly impact on the cleavability of SNAP-25 by BoNT/C.
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cleavability. Recombinant SNAP-25 substrate (30 ng/ ple) was incubated with reduced full length
BoNT/A (B) or BoNT/E (C) (10 ng/sa ple). At indicated time points, the reaction was blocked
by adding loading sample buffer and heat denaturation. Samples were separated by SDS-PAGE
and proteins stained with Coomassie Blue. Ratio of uncleaved to total SNAP-25 was evaluated by
densitometric analysis. Ratios are shown in the bar chart as mean with respective standard deviation of
3 independent experiments. In some experiments, after electrophoresis, samples were immunoblotted
for His (recognizing both intact and truncated SNAP-25), BoNT/A-cleaved SNAP-25 or whole SNAP-25
(recognizing only native SNAP-25) detection. Antibodies were visualized using fluorescent secondary
antibodies for detection by the Odyssey Imaging System. The assays were performed at least 3 times
and representative blots are shown in the bottom panels.
3. Discussion
Previous work indicated that TeNT and BoNT have acted to select mutants of the VAMP-1
protein, which are resistant to their proteolytic activity and therefore to the neuroparalysis induced by
tetanus and botulism. It was found that rats and chicken are resistant to tetanus because VAMP-1 is
the predominant isoform in the spinal cord and their VAMP-1 carry the peptide bond Val77-Phe78,
not cleavable by TeNT, rather than the TeNT sensitive peptide bond Gln77-Phe78 present in most
species, including humans [27]. The results reported here show no record of human mutants at any
of the cleavage sites of the many BoNTs targeting neuronal VAMPs or syntaxins, indicating that
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these neurotoxins may have not acted as selective agents in human evolution. This result is expected
for botulism, which is indeed a disease of animals with an accidental impact in humans [49,50].
The contrary was expected for tetanus, a disease that has been a major human killer during history,
beginning with the descriptions of Hippocrates and Aretaeus [51,52], until the introduction of tetanus
vaccine. Tetanus can occur at any age and it has been particularly evident among neonates in the
horrible form of tetanus neonatorum, which has taken lives in the number of hundreds of thousand,
and still is not completely eradicated [53,54].
The single mutation detected in a BoNT cleavage site in the present search in only two cases over
>120,000 human subjects, is located in SNAP-25 at the residue Arg198 replaced by a cysteine residue.
Even though we cannot validate such a mutation experimentally, the possibility of sequencing errors
can be safely ruled out by the very stringent criteria by which data have been processed [3]. We provide
evidence that this variation affects BoNT/A activity, and very likely that of BoNT/C, making SNAP-25
R198C resistant to these neurotoxins, at least under the experimental conditions we used. BoNT/A,
like all the other BoNTs, is naturally present as many toxin variants, known as subtypes, and here we
tested only subtype 1 [7,55]. Given that the BoNT/A variants characterized so far invariably cleave
SNAP-25 at the Q197-R198, it is reasonable to assume that the present result may be extended to the
other members of the BoNT/A family. However, this should be experimentally tested.
Cysteine Palmitoylation by Golgi S-palmitoyl transferases is a main determinant of SNAP-25
membrane association and trafficking to the plasma membrane [56,57]. Whether the additional
Cysteine in the R198C mutant is palmitoylated in vivo and which functional consequences this
modification may cause are difficult to predict. However, one might speculate that a further anchorage
site to the plasma membrane at the C-terminus of SNAP-25 would sequester the second SNARE
motif preventing its coil coiling with the other SNARE proteins. In this case, the mutation would
further preclude the activity of BoNT/A as the cleavage of SNAP-25 by its protease relies on multiple
enzyme-substrate interactions involving SNAP-25 C-terminus [7,10,58].
Finally, taking into account the number of genomes considered, the rarity of R198C mutation and
the fact that no Cys198 homozygous subjects have been isolated so far, one can safely conclude that
the human patients primary resistant to BoNT/A are not carrying mutations that prevent BoNT/A
cleavage of SNAP-25.
4. Conclusions
The availability of human genome database has allowed us to check the possibility that the TeNT
and BoNTs have acted as selective evolutionary agents in humans. This possibility is not supported
by the present analysis as we have found no mutation in their specific cleavage sites which appear
to be essential for the SNARE function. In fact, the present data indicate that tetanus and botulinum
neurotoxins have been selected through bacterial evolution to act in such a way as to cause a major
impairment to the very essential process of neurotransmitter release. Their cleavage of VAMPs and
syntaxins leads to the removal from the membrane of a large portion of the molecule, which is no longer
available to act within the membrane active neuroexocytosis nanomachine. The same explanation
applies to BoNT/E which removes a large portion of SNAP-25, but not to BoNT/A which removes
only nine residues from the SNAP-25 C-terminus. Several explanations have been advanced to account
for the possible consequence of this truncation, but a satisfactory rationale has still to be provided.
5. Materials and Methods
5.1. Generation of SNARE Protein Mutation Maps
Mutation frequency tables of depicted proteins were obtained from http://www.exac.
broadinstitute.org/ and http://gnomad.broadinstitute.org/. Schematic figures, including the protein
domains were made using http://www.uniprot.org/.
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5.2. Molecular Cloning
As recombinant target substrate for BoNT/A and BoNT/E, a His-tagged construct consisting of
N-terminal CPV and C-terminal the second SNARE motif of SNAP25 (amino acids 136–206) connected
by a GSG linker was designed. The constructs for wild type and R198C were synthesized by GeneArt
Thermofisher and delivered in a donor vector. Using standard cloning techniques, the gene of
interest was cloned into a pET28a expression vector by BamHI/HindIII restriction digestion and
subsequent ligation.
5.3. Expression and Affinity Purification of Recombinant His_CPV_SNAP25(136–206) Wild Type and R198C
Expression plasmids were transformed into E. coli BL21. A single clone was picked and used for
overnight culture at 37 ◦C and 180 rpm (Gallenkamp orbital shaker incubator) in 5 mL LB (10 g/L
Tryptone, 5 g/L Yeast extract, 5 g/L NaCl, 15 g/L Agar) + Kanamycin (100 µg/mL) in a culture tube.
The next day the total volume was transferred into 500 mL of LB + Kanamycin in a 1 L Erlenmeyer flask
and further incubated at 30 ◦C and 220 rpm till the OD600 reached 0.5–0.6. Expression was then induced
using 0.5 mM IPTG and the culture was further incubated at 30 ◦C and 220 rpm overnight. E. coli
was harvested by centrifuging for 15 min at 5500 RCF. The pellet was solubilized in 10 mL Binding
Buffer (20 mM Tris-HCl, 500 mM NaCl, pH 7.8) and frozen until use. For purification the pellet was
thawed and substituted with Roche complete protease inhibitor cocktail (EDTA free). The solution was
sonicated in an ice-cooled falcon at 80% amplitude and 0.5 s cycles 8 times (30 s pauses between each
time). The mixture was pelleted by centrifugation at 16,000 RCF for 30 min at 4 ◦C. The supernatant
was then 0.22 µm filtered and adjusted to pH 7.8. Purification was performed with the ÄKTA FPLC
system using a HiTrap Talon Crude 1 mL column and a standard flow of 1 mL/min. The system was
flushed with binding buffer (5 CV). Sample was loaded and flow-through collected for an additional
run. Subsequently, the system was washed with 15 CV of washing buffer (20 mM Tris-HCl, 500 mM
NaCl, 5 mM Imidazole, pH 7.8). Gradient elution was performed from 0–100% with elution buffer
(20 mM Tris-HCl, 500 mM NaCl, 500 mM Imidazole, pH 7.8) within 20 CV. Fractions were collected
and analyzed using Coomassie gels. Product containing fractions were pooled and 3 steps dialyzed
against Hepes buffer (10 mM Hepes, 120 mM NaCl, pH 7.4). Aliquots were stored at −80 ◦C.
5.4. BoNT Proteolysis Assay
BoNT/A was prepared and purified as described [59] whilst BoNT/E was produced in E. coli
via recombinant methods [23]. BoNTs were reduced using the assay buffer (150 mM NaCl, 10 mM
NaH2PO4, 0.3 mM ZnCl2, 15 mM DTT, complete protease inhibitor [EDTA free], pH 7.4) and incubation
at 37 ◦C for 30 min. The BoNT solution was then mixed with assay buffer containing an appropriate
amount of wild type or mutant substrate and incubated at 37 ◦C. The whole experiment was performed
in a single test tube. At the indicated time points, samples were taken from the test tube and the
reaction was stopped by adding 6× protein loading buffer and incubation at 95 ◦C for at least 5 min.
The residual mixture was further incubated at 37 ◦C till all samples were taken and applied to
SDS-PAGE and Western blot depending on the experiment.
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